clinical trial · NCT05428033
A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
Otsuka Pharmaceutical Development & Commercialization, Inc.·phase3·completed·n = 574
Attention Deficit/Hyperactivity Disordercentanafadine capsuleplacebo capsule
brief summary
This trial will be conducted to evaluate the efficacy of centanafadine once daily (QD) extended release (XR) versus placebo in the treatment of child subjects (4 to 12 years, inclusive) with ADHD. The trial will consist of a screening period, a double-blind treatment period, and follow-up period.
started
Jul 11, 2022
primary completion
Mar 17, 2025
completion
Mar 17, 2025
last updated
Apr 13, 2026
official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Efficacy and Safety of Once Daily Centanafadine Capsules for the Treatment of Children With Attention-deficit/Hyperactivity Disorder (ADHD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol